Skip to main content
EJNMMI Research
Figure 7 | EJNMMI Research

Figure 7

From: Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors

Figure 7

Proliferation and apoptosis of tumor β-cells treated with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and/or imatinib. (A) Proliferation of tumor beta-cells of Rip1Tag2 mice treated with [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 and [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 plus imatinib is reduced compared to the natIn-exendin-4 and the imatinib group (*p < 0.05, Newman-Keuls post-test). (B) However, the combined treatment modality does not increase tumor cell apoptosis compared to the other groups (p > 0.05, Newman-Keuls post-test). (C) Immunohistochemistry for proliferation (BrdU, top row) and apoptosis (TUNEL, bottom row) on the sections of Rip1Tag2 pancreas treated as indicated on the graph. Size bars, 100 μm.

Back to article page